AT
Senior Director, Operations
DB
Director, Clinical & Regulatory Operations
Get the full picture
Sign in to uncover key details.
AdAlta
Business Services · Australia · 1-10 Employees
View Company Info for Free
Overview
Headquarters
697 Burke Rd Se 201, Camberwell, Victori...Phone Number
+61 394795159Website
www.adalta.com.auRevenue
<$5 MillionStock Symbol
1ADIndustry
About AdAlta
AdAlta is focused on developing innovative solutions for debilitating diseases through its i-body® drug discovery platform, which offers new therapeutic options where traditional antibodies fall short. The company specializes in next-generation protein and cell therapies, particularly targeting fibrosis and immuno-oncology. Their lead asset, AD-214, is a first-in-class product aimed at treating fibrotic diseases and providing hope for patients with solid tumors. Additionally, AdAlta is advancing i-CAR-T cell therapies and i-PET imaging to enhance cancer treatment outcomes.Explore more
AdAlta Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to AdAlta
Compare insights from companies similar to AdAlta, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
AdAlta Tech Stack
A closer look at the technologies used by AdAlta
See more technologies
Top Business Services Companies
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding AdAlta
Sign Up For FreeTo access detailed company insights
AdAlta is focused on developing innovative solutions for debilitating diseases through its i-body® drug discovery platform, which offers new therapeutic options where traditional antibodies fall short. The company specializes in next-generation protein and cell therapies, particularly targeting fibrosis and immuno-oncology. Their lead asset, AD-214... Read More
